;. Canada and . Tourbah, Neurology, vol.86, issue.16, pp.15-21, 2016.

C. Confavreux, S. Vukusic, and T. Moreau, Relapses and progression of disability in multiple sclerosis, N Engl J Med, vol.343, pp.1430-1438, 2000.

M. Koch, E. Kingwell, and P. Rieckmann, The natural history of primary progressive multiple sclerosis, Neurology, vol.73, pp.1996-2002, 2009.

F. D. Lublin, New multiple sclerosis phenotypic classification, Eur Neurol, vol.72, pp.1-5, 2014.

M. C. Levin, J. N. Douglas, and L. Meyers, Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms, Degener Neurol Neuromuscul Dis, vol.4, pp.49-63, 2014.

P. K. Stys, G. W. Zamponi, and M. J. Van, Will the real multiple sclerosis please stand up?, Nat Rev Neurosci, vol.13, pp.507-521, 2012.

B. D. Trapp and P. K. Stys, Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis, Lancet Neurol, vol.8, pp.280-91, 2009.

A. Tourbah, C. Lebrun-frenay, and G. Edan, MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study, Mult Scler J, vol.22, pp.1719-1750, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01414958

F. Sedel, D. Bernard, and D. M. Mock, Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis, Neuropharmacology, vol.110, pp.644-53, 2015.

L. Tong, Structure and function of biotin-dependent carboxylases, Cell Mol Life Sci, vol.70, pp.863-91, 2013.

J. E. Dewille and L. A. Horrocks, Synthesis and turnover of myelin phospholipids and cholesterol, 1992.

L. J. Balcer, Clinical practice. Optic neuritis, N Engl J Med, vol.354, pp.1273-80, 2006.

H. Hoorbakht and F. Bagherkashi, Optic neuritis, its differential diagnosis and management, Open Ophthalmol J, vol.6, pp.65-72, 2012.

S. J. Hickman, C. M. Dalton, and D. H. Miller, Management of acute optic neuritis, Lancet, vol.360, pp.1953-62, 2002.

I. Pirko, L. A. Blauwet, and T. G. Lesnick, The natural history of recurrent optic neuritis, Arch Neurol, vol.61, pp.1401-1406, 2004.

H. Wilhelm and M. Schabet, The diagnosis and treatment of optic neuritis, Dtsch Arztebl Int, vol.112, pp.616-641, 2015.

R. W. Beck, R. L. Gal, and M. T. Bhatti, Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial, Am J Ophthalmol, vol.137, pp.77-83, 2004.

E. M. Frohman, T. C. Frohman, and D. S. Zee, The neuro-ophthalmology of multiple sclerosis, Lancet Neurol, vol.4, pp.111-132, 2005.

I. E. Ormerod and W. I. Mcdonald, Multiple sclerosis presenting with progressive visual failure, J Neurol Neurosurg Psychiatry, vol.47, pp.943-949, 1984.

N. R. Miller, N. J. Newman, V. Biousse, and J. B. Kerrison, Walsh & Hoyt's clinical neuro-ophthalmology: the essentials, 2007.

R. R. Shamir, Y. Friedman, and L. Joskowicz, Comparison of Snellen and early treatment diabetic retinopathy study charts using a computer simulation, Int J Ophthalmol, vol.9, pp.119-142, 2016.

L. Frisen, Identification of functional visual field loss by automated static perimetry, Acta Ophthalmol, vol.92, pp.805-814, 2014.

O. Mienberg, J. Flammer, and H. P. Ludin, Subclinical visual field defects in multiple sclerosis. Demonstration and quantification with automated perimetry, and comparison with visually evoked potentials, J Neurol, vol.227, pp.125-158, 1982.

F. Sedel, C. Papeix, and A. Bellanger, High doses of biotin in chronic progressive multiple sclerosis: a pilot study, Mult Scler Relat Disord, vol.4, pp.159-69, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01251510

C. H. Polman, S. C. Reingold, and B. Banwell, Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Ann Neurol, vol.69, pp.292-302, 2011.

J. V. Odom, M. Bach, and M. Brigell, ISCEV standard for clinical visual evoked potentials, update). Doc Ophthalmol, vol.120, pp.111-120, 2009.

R. W. Beck, P. A. Cleary, and A. Mm, A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group, N Engl J Med, vol.326, pp.581-589, 1992.

R. Zivadinov, M. G. Dwyer, S. Hussein, C. E. Kennedy, C. Andrews et al., Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNb-1a in multiple sclerosis, Mult Scler, vol.18, pp.1125-1159, 2012.

V. E. Miron, S. K. Ludwin, P. J. Darlington, A. A. Jarjour, B. Soliven et al., Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices, Am J Pathol, vol.176, pp.2682-94, 2010.

G. Birnbaum and J. Stulc, High dose biotin as treatment for progressive multiple sclerosis, Mult Scler Relat Disord, vol.18, pp.141-144, 2017.

F. Granella, E. Tsantes, E. Siena, and E. Curti, Breakthrough disease under high-dose biotin treatment in progressive multiple sclerosis, Mult Scler, vol.23, issue.S3, pp.85-426, 2017.

A. Tourbah and F. Sedel, Letter to the Editors-Multiple sclerosis and related disorders-Birnbaum et al, Mult Scler Relat Disord, vol.20, p.204, 2017.

P. Branger, N. Derache, N. Kassis, E. Maillart, R. Assouad et al., Relapses during high doses of biotin in progressive multiple sclerosis: a case series, 70th AAN annual meeting, 2018.

R. Lasser, F. Sedel, G. Brion, J. Patterson, and A. Tourbah, Annual relapse rates (ARR) in patients with spinal progressive multiple sclerosis treated with MD1003 (high-dose pharmaceutical biotin)

, Mult Scler, vol.24, issue.S1, pp.11-117, 2018.